IOIan P. O'KEefe

Ian P. O'KEefe

*This is an algorithmically generated author record based on publicly available information.

Ian P. O'KEefe has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acquired mutations in transcriptional regulator hns and lipopolysaccharide biosynthesis and modification genes impact colistin resistance and fitness of mcr -carrying E. coli

    by Anna Schumann, Ian P. O’KEefe, Robert K. Ernst, Martin Wiedmann

    Gram-negative bacteria can develop resistance to the last-resort antimicrobial colistin through the acquisition of mobile colistin resistance ( mcr ) genes or chromosomal mutations. Bacteria carrying mcr variants do not always have colistin minimum inhibitory concentrations (MICs) above the clinical breakpoint, and there is a gap in understanding how mcr -carrying bacteria adapt to colistin selective pressure. To address this gap, we propagated Escherichia coli strains carrying mcr-3 or mcr-9 , which have been reported to confer different levels of colistin resistance and fitness costs, and a control strain lacking an mcr gene in the presence of increasing concentrations of colistin. While the mcr-9 and control strains maintained their baseline colistin MICs, the colistin MIC of the strain expressing mcr-3 increased, alongside acquisition of nonsynonymous mutations in genes involved in lipopolysaccharide biosynthesis and modification. Analysis of individual mcr-3 strains that evolved during the experiment revealed that mutants exhibited improved competitive performance under colistin selection, but showed reduced fitness in standard media, or in the presence of human serum. Nonsynonymous lpxC and hns mutations were significant predictors of overall fitness and bacterial growth, but were infrequent among wild-type E. coli isolates, and even less frequent in mcr- positive wild-type E. coli . Our results suggest that mcr -expressing E. coli can evolve to show increased colistin MICs; however, fitness costs may prevent these mutations from being established in natural populations. Moreover, E. coli might control mcr-3 expression through the nucleoid protein H-NS, providing novel insights into bacterial regulation of mcr expression.

  • Open Access

    Characterization of Pseudomonas aeruginosa from subjects with diffuse panbronchiolitis

    by Charles M. Met, Casey E. Hofstaedter, Ian P. O'KEefe, Hyojik Yang, Dina A. Moustafa, Matthew E. Sherman, Yohei Doi, David A. Rasko, Charles R. Sweet, Joanna B. Goldberg, et al.

    Diffuse panbronchiolitis (DPB) is a rare, idiopathic inflammatory disease primarily diagnosed in East Asian populations. DPB is characterized by diffuse pulmonary lesions, inflammation of the respiratory bronchioles, and bacterial infections of the airway. Historically, sputum cultures reveal Pseudomonas aeruginosa in 22% of DPB patients, increasing to 60% after 4 years from disease onset. Although DPB patients have a known susceptibility to respiratory P. aeruginosa infections, as is observed in other chronic lung diseases such as cystic fibrosis (CF), the characterization of DPB P. aeruginosa strains is limited. In this study, we characterized 24 strains obtained from a cohort of DPB patients for traits previously associated with virulence, including growth, motility, antibiotic susceptibility, lipopolysaccharide structure, and genomic diversity. Our cohort of DPB P. aeruginosa strains exhibits considerable genomic variability when compared with isolates from people with cystic fibrosis chronically colonized with P. aeruginosa and acute P. aeruginosa infection isolates. Similar to CF, DPB P. aeruginosa strains produce a diverse array of modified lipid A structures. Antibiotic susceptibility testing revealed increased resistance to erythromycin, a representative agent of the macrolide antibiotics used to manage DPB patients. Differences in the O-antigen type among P. aeruginosa strains collected from these different backgrounds were also observed. Ultimately, the characterization of DPB P. aeruginosa strains highlights several unique qualities of P. aeruginosa strains collected from chronically diseased airways, underscoring the challenges in treating DPB, CF, and other obstructive respiratory disease patients with P. aeruginosa infections. IMPORTANCE: Diffuse panbronchiolitis (DPB), a chronic lung disease characterized by persistent P. aeruginosa infection, serves as an informative comparator to more common chronic lung diseases, such as cystic fibrosis (CF). This study aimed to better address the interplay between P. aeruginosa and chronically compromised airway environments through the examination of DPB P. aeruginosa strains, as existing literature regarding DPB is limited to case reports, case series, and clinical treatment guidelines. The evaluation of these features in the context of DPB, in tandem with prevailing knowledge of P. aeruginosa strains collected from more common chronic lung diseases (e.g., CF), can aid in the development of more effective strategies to combat respiratory P. aeruginosa infections in patients with chronic lung diseases.